First Time Loading...

Inhibrx Inc
NASDAQ:INBX

Watchlist Manager
Inhibrx Inc Logo
Inhibrx Inc
NASDAQ:INBX
Watchlist
Price: 34.04 USD
Updated: May 1, 2024

Inhibrx Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Inhibrx Inc
Cash from Financing Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Inhibrx Inc
NASDAQ:INBX
Cash from Financing Activities
$202m
CAGR 3-Years
7%
CAGR 5-Years
73%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$17.2B
CAGR 3-Years
-14%
CAGR 5-Years
-4%
CAGR 10-Years
-17%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$5.1B
CAGR 3-Years
N/A
CAGR 5-Years
16%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
$21B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
23%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$562.2m
CAGR 3-Years
-4%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.8B
CAGR 3-Years
3%
CAGR 5-Years
-88%
CAGR 10-Years
N/A

See Also

What is Inhibrx Inc's Cash from Financing Activities?
Cash from Financing Activities
202m USD

Based on the financial report for Dec 31, 2023, Inhibrx Inc's Cash from Financing Activities amounts to 202m USD.

What is Inhibrx Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
73%

Over the last year, the Cash from Financing Activities growth was -22%. The average annual Cash from Financing Activities growth rates for Inhibrx Inc have been 7% over the past three years , 73% over the past five years .